MK-1084 Clinical Trials

2 actively recruiting trials across 1 location

▼ -1 trial since June 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

Merck Sharp & Dohme LLC2

Indications

Lung Cancer2
Cancer2
Lung Neoplasm Malignant1
Malignant Neoplasm1

Clermont, Florida2 trials

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Clermont Oncology Center ( Site 0041)

Phase 1/2

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Clermont Oncology Center ( Site 0041)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.